Status: Recruiting
UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in AIHA who have failed ≥ 3 lines of therapy
Participants needed: 15
Trial details
Phase: Early Phase 1Age: 10+Biological sex: AllType: InterventionalSponsor: The Second Hospital of Anhui Medical UniversityUpdated: Apr 15, 2026Locations: 1
Eligibility criteria
1. Age ≥ 10 years, regardless of sex; [+9]
1. Subjects with a history of severe drug allergies or allergic tendencies; [+14]